Black Rock Inc. Ambrx Biopharma Inc. Transaction History

Black Rock Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.96 $56 - $156	-53 Reduced -0.0%	2,851,433 $3.08 Million
Q1 2022 May 12, 2022	SELL	$4.07 - $9.0 $73,260 - $162,000	-18,000 Reduced 0.63%	2,851,486 $11.7 Million
Q4 2021 Feb 10, 2022	BUY	$8.11 - $13.91 $16.6 Million - $28.5 Million	2,049,265 Added 249.84%	2,869,486 $25.9 Million
Q3 2021 Nov 09, 2021	SELL	$13.31 - $22.53 $405,356 - $686,151	-30,455 Reduced 3.58%	820,221 $11.1 Million
Q2 2021 Aug 11, 2021	BUY	$15.95 - $19.6 $13.6 Million - $16.7 Million	850,676 New	850,676 $16.7 Million

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.